Nucleic acid sample preparation
First Claim
Patent Images
1. A method for detecting a cell free biomarker, the method comprising:
- a. applying a sample with a conductivity of greater than 100 mS/m to a device, the device comprising an array of electrodes capable of establishing an AC electrokinetic field region, the device further comprising at least two chambers, the sample applied to a first chamber;
b. applying known quantities of a cell-free biomarker standard to a second chamber;
c. establishing a first AC electrokinetic high field region in the first chamber, the first AC electrokinetic high field capable of isolating larger nanoparticulate molecular targets;
d. establishing a second AC electrokinetic low field in the first chamber, the second AC electrokinetic low field capable of concentrating cells or micron-sized entities that may be present in the sample;
e. establishing a third AC electrokinetic high field to the second chamber, the second AC electrokinetic high field isolating the molecular nucleic acid standard applied to the second chamber;
f. flushing cells and micron-sized entities that may be present in the sample from the first chamber;
g. detecting bound cell-free biomarker signal on the array in the first chamber and second chamber; and
h. quantifying the bound cell-free biomarker by comparing the detected signal from the first chamber to detected signal from the second chamber.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention includes methods, devices and systems for isolating a nucleic acid from a fluid comprising cells. In various aspects, the methods, devices and systems may allow for a rapid procedure that requires a minimal amount of material and/or results in high purity nucleic acid isolated from complex fluids such as blood or environmental samples.
69 Citations
20 Claims
-
1. A method for detecting a cell free biomarker, the method comprising:
-
a. applying a sample with a conductivity of greater than 100 mS/m to a device, the device comprising an array of electrodes capable of establishing an AC electrokinetic field region, the device further comprising at least two chambers, the sample applied to a first chamber; b. applying known quantities of a cell-free biomarker standard to a second chamber; c. establishing a first AC electrokinetic high field region in the first chamber, the first AC electrokinetic high field capable of isolating larger nanoparticulate molecular targets; d. establishing a second AC electrokinetic low field in the first chamber, the second AC electrokinetic low field capable of concentrating cells or micron-sized entities that may be present in the sample; e. establishing a third AC electrokinetic high field to the second chamber, the second AC electrokinetic high field isolating the molecular nucleic acid standard applied to the second chamber; f. flushing cells and micron-sized entities that may be present in the sample from the first chamber; g. detecting bound cell-free biomarker signal on the array in the first chamber and second chamber; and h. quantifying the bound cell-free biomarker by comparing the detected signal from the first chamber to detected signal from the second chamber. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
-
Specification